Rising prostate-specific antigen (PSA) in nonmetastatic prostate cancer occurs in two main clinical settings: (1) rising PSA to signal failed initial local therapy and (2) rising PSA in the setting of early hormone-refractory prostate cancer prior to documented clinical metastases. Most urologists and radiation oncologists are very familiar with the initial very common clinical scenario, commonly called "biochemical recurrence." In fact, up to 70,000 men each year will have a PSA-only recurrence after failed definitive therapy. The ideal salvage therapy for these men is not clear and includes salvage local therapies and systemic approaches, of which the mainstay is hormonal therapy. Treatment needs to be individualized based upon the patient's risk of progression and the likelihood of success and the risks involved with the therapy. It is unknown how many men per year progress with rising PSA while on hormonal therapy without documented metastases. This rising PSA disease state is sometimes called, "PSA-only hormone-refractory prostate cancer." As in the setting of initial biochemical recurrence, evidence-based treatment options are limited, and taking a risk-stratified approach is justified. In this article, we will explore these prostate cancer disease states with an emphasis on practical, clinically applicable approaches.
In 2007, nearly 219,000 men are expected to be diagnosed with prostate cancer, approximately 90% will undergo definitive local therapy, and around 30% to 35% will develop biochemical (ie, prostate-specific antigen [PSA]) recurrence within 10 years. Thus, approximately 60,000 to 70,000 men each year develop initial PSA recurrence. Similarly, almost 30,000 men die of prostate cancer annually. Presumably almost all these men progress through hormonal therapy and succumb to the disease in the hormone-refractory disease state
The natural history of the hormone-refractory nonmetastatic disease state is such that it may take 2 to 3 years between initial elevation in PSA on hormones to documented clinical metastatic disease. As such, there may be 60,000 to 90,000 men alive at any one time in this country with secondarily rising PSA nonmetastatic prostate cancer. In summary, this collective disease state is common, affecting many current era patients and the subject of many clinical encounters by urologists, radiation oncologists, and medical oncologists.
Definition of Primary PSA Recurrence
The goal of radical prostatectomy (RP) is to remove the entire prostate. Therefore, slight rises in PSA are used to indicate cancer recurrence, although the exact level that defines PSA recurrence is debatable. In general, PSA levels > 0.4 ng/mL or > 0.2 ng/mL are used in most studies. Recently, the American Urological Association published guidelines that establish the consensus definition of PSA recurrence after RP to be greater than 0.2 ng/mL and rising, as confirmed on a repeat test. This definition is to establish recurrence for outcomes reporting; however, it may not be the appropriate cutpoint to initiate therapy.
Indeed, it is our practice in a patient with a consistent and clearly rising PSA, often based on ultrasensitive values, to occasionally begin salvage radiotherapy when the PSA is between 0.1 and 0.2 ng/mL. Because microscopic or focal benign prostate tissue can sometimes be left behind after RP and may produce some small amounts of PSA, it is clinically important to recognize that a PSA of 0.2 ng/mL may not always represent cancer recurrence. Therefore, in the majority of patients, we do wait until the PSA is > 0.2 ng/mL before beginning salvage treatments.
Unfortunately, defining recurrence following radiation therapy (RT) is more difficult. Unlike after RP, PSA does not fall to undetectable levels after RT. Rather, radiation induces a slow and not always steady PSA decline. The median time to PSA nadir is around 18 months and possibly longer following brachytherapy. Also, slight transient PSA upswings ("PSA bounce") are not uncommon. Finally, the concomitant use of hormonal therapy and the variable time period of return to normal testosterone can complicate the interpretation of PSA recurrence.
In 1997, the American Society for Therapeutic Radiology and Oncology (ASTRO) convened a consensus panel to develop a recurrence definition. The definition developed by the panel required three consecutive PSA increases after reaching a nadir, or a single rise so great as to trigger the initiation of hormone therapy. The date of PSA failure is backdated to the midpoint between the PSA nadir and the first of the three rises. This backdating of the failure time introduces a bias that overestimates the success at shorter follow-up times (ie, PSA may be rising, but not enough follow-up has occurred to document three consecutive rises). In long-term studies, this definition introduces a bias in that no patient can recur "late" because all late recurrences are backdated to an earlier time, resulting in a leveling of the survival curve.
Because of these concerns, ASTRO convened a new consensus panel that developed new recurrence definitions: a PSA value higher than absolute nadir plus 2 ng/mL, or a PSA value higher than absolute nadir plus 3 ng/ mL. This new definition is called the "Phoenix" definition in some circles because the consensus panel meeting was held in Phoenix, Ariz. Importantly, both definitions date the failure as the time the PSA rose above the threshold for recurrence (ie, failure is no longer backdated).
Natural History of Initial PSA Recurrence
The natural history of PSA recurrence is usually long but varied. Pound and associates described 304 men with PSA recurrence following RP from Johns Hopkins Hospital who did not receive hormonal therapy until the time of metastasis. Moreover, very few received salvage radiation therapy. The median time from PSA recurrence to metastasis was 8 years, and from metastasis to death was 5 years. In a recent follow-up study by Freedland et al that included a slightly larger cohort, the median time from PSA recurrence to prostate cancer death was not reached after 16 years. In the latter study, however, although rare, prostate cancer deaths were seen as early as 1 year after PSA recurrence.
Thus, although the natural history of recurrent prostate cancer is often one of a slowly progressing disease, in some men it can be very rapid. Moreover, patients today are younger than in the past, with a median age at diagnosis of 65 years. In younger men with few competing mortality risks, even a slowly progressive cancer can ultimately lead to cancer death.
Risk Factors for Clinical Progression and Prostate Cancer Death After Initial Rising PSA
Fifteen years ago, Carter and colleagues showed that changes in PSA over time could predict the likelihood of being diagnosed with prostate cancer. Shortly thereafter, PSA kinetics were shown to predict the risk of distant vs local failure among men with PSA recurrence after RT and RP. These initial observations have been confirmed in later studies.[9,15,16] Recently, a rapid PSA doubling time (PSADT) has also been linked with prostate cancer death.[10,15,17]
The best cutpoint to define "rapid" PSADT is unclear. Various cutpoints have been described: 3 months, 6 months,[18,19] 8 months, 10 months, and 12 months. Given multiple cutpoints, it is likely that the association between PSADT and risk of poor outcome is on a continuum. Indeed, D'Amico and colleagues, found that among men with a PSADT > 3 months after either RT or RP, PSADT as a continuous variable was significantly associated with prostate cancer death. More recently, this continuum between PSADT and risk was demonstrated by Freedland and coworkers who identified three PSADT cutpoints separating men into four risk groups.
Another issue regarding the use of PSADT is how to calculate PSADT: How many PSA measurements are needed and over what time period? Unfortunately, no clear standard methodology exists. Prior studies found that in the early time period after PSA recurrence, PSA rises exponentially with first-order kinetics.[19,21] Thus, PSADT—which is based upon the natural log of PSA—is constant over time. Therefore, it is reasonable to calculate PSADT using two values as long as the two values are sufficiently spaced in time to avoid subtle variations in laboratory measurements from being interpreted as a rapid PSADT.
It is our practice to use the first two PSA measurements after recurrence (ie, ≥ 0.2 ng/mL) separated by at least 3 months before calculating a PSADT, with the exception of the patient with an extremely fast rise in PSA, in whom a shorter interval may suffice to determine PSADT. Whether a similar approach can be used for estimating PSADT using supersensitive PSA assays for values < 0.2 ng/mL is unknown.
Another unresolved issue is whether other variables, such as Gleason sum or time to PSA recurrence, add useful information to the PSADT. To a certain degree, the debate is academic in that all three variables are highly correlated: The patient with a rapid PSADT likely has recurred early with a high Gleason. Thus, if this patient has a poor outcome, should we ascribe it to the rapid PSADT, the early recurrence, or the high Gleason? While it is generally accepted that PSADT is the best prognostic factor currently available, some (but not all)[15,22] studies have found that the Gleason sum[9,10,23] and time to PSA recurrence[9,10,19,20] add information to the PSADT.
Although PSADT is a valuable prognostic factor, what about the absolute PSA level? In studies that attempt to estimate the risk of a future event (ie, metastasis or prostate cancer death), zero is often defined as the time of recurrence, and thus all men have similar small-sized tumors. However, if one does not define time zero as the time of recurrence, but rather as whatever the current time is, then not all men have equal-sized tumors (ie, some men are evaluated at the time of recurrence and others years later). In that case, the size of the tumor, as approximated by the absolute PSA level, becomes a significant predictor of time to metastatic disease, or the likelihood that a bone scan or computed tomography (CT) scan done today will demonstrate metastatic disease.
1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007.
2. Greene KL, Cowan JE, Cooperberg MR, et al: Who is the average patient presenting with prostate cancer? Urology 66:76-82, 2005.
3. Han M, Partin AW, Pound CR, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001.
4. Amling CL, Bergstralh EJ, Blute ML, et al: Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 165:1146-1151, 2001.
5. Freedland SJ, Sutter ME, Dorey F, et al: Defining the ideal cutpoint for determining psa recurrence after radical prostatectomy. Urology 61:365-369, 2003.
6. Cookson MS, Aus G, Burnett AL, et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540-545, 2007.
7. Horwitz EM, Vicini FA, Ziaja EL, et al: The correlation between the ASTRO consensus panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American society of therapeutic radiology and oncology. Int J Radiat Oncol Biol Phys 41:267-272, 1998.
8. Horwitz EM, Thames HD, Kuban DA, et al: Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173:797-802, 2005.
9. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after psa elevation following radical prostatectomy. JAMA 281:1591-1597, 1999.
10. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005.
11. Freedland SJ, Humphreys EB, Mangold LA, et al: Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25:1765-1771, 2007.
12. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992.
13. Zagars GK, Pollack A: The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72:832-842, 1993.
14. Trapasso JG, deKernion JB, Smith RB, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152:1821-1825, 1994.
15. Ward JF, Blute ML, Slezak J, et al: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170:1872-1876, 2003.
16. Okotie OT, Aronson WJ, Wieder JA, et al: Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171:2260-2264, 2004.
17. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003.
18. D'Amico AV, Cote K, Loffredo M, et al: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20:4567-4573, 2002.
19. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997.
20. Zagars GK, Pollack A: Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997.
21. Soergel TM, Koch MO, Foster RS, et al: Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. J Urol 166:2198-2201, 2001.
22. Zhou P, Chen MH, McLeod D, et al: Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23:6992-6998, 2005.
23. Pinover WH, Horwitz EM, Hanlon AL, et al: Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97:1127-1133, 2003.
24. Slovin SF, Wilton AS, Heller G, et al: Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 11:8669-8673, 2005.
25. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19:1030-1039, 2001.
26. Koppie TM, Grossfeld GD, Nudell DM, et al: Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 166:111-115, 2001.
27. Katz MS, Zelefsky MJ, Venkatraman ES, et al: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21:483-489, 2003.
28. Stephenson AJ, Shariat SF, Zelefsky MJ, et al: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291:1325-1332, 2004.
29. Anscher MS, Clough R, Dodge R: Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 48:369-375, 2000.
30. Cox JD, Gallagher MJ, Hammond EH, et al: Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American society for therapeutic radiology and oncology consensus panel. J Clin Oncol 17:1155, 1999.
31. Pazona JF, Han M, Hawkins SA, et al: Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174:1282-1286, 2005.
32. Stephenson AJ, Scardino PT, Kattan MW, et al: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041, 2007.
33. Ward JF, Sebo TJ, Blute ML, et al: Salvage surgery for radiorecurrent prostate cancer: Contemporary outcomes. J Urol 173:1156-1160, 2005.
34. Bianco FJ Jr, Scardino PT, Stephenson AJ, et al: Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 62:448-453, 2005.
35. Stephenson AJ, Scardino PT, Bianco FJ Jr, et al: Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 172:2239-2243, 2004.
36. Han KR, Cohen JK, Miller RJ, et al: Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. J Urol 170:1126-1130, 2003.
37. Anastasiadis AG, Sachdev R, Salomon L, et al: Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer. J Cancer Res Clin Oncol 129:676-682, 2003.
38. Touma NJ, Izawa JI, Chin JL: Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 173:373-379, 2005.
39. Ismail M, Ahmed S, Kastner C, et al: Salvage cryotherapy for recurrent prostate cancer after radiation failure: A prospective case series of the first 100 patients. BJU Int 100:760-764, 2007.
40. Huggins C, Hodges CV: Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168:9-12, 2002.
41. Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 294:238-244, 2005.
42. Bayoumi AM, Brown AD, Garber AM: Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 92:1731-1739, 2000.
43. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Prostate cancer trialists' collaborative group. Lancet 355:1491-1498, 2000.
44. Klotz L, Schellhammer P: Combined androgen blockade: The case for bicalutamide. Clin Prostate Cancer 3:215-219, 2005.
45. Loblaw DA, Virgo KS, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an american society of clinical oncology practice guideline. J Clin Oncol 25:1596-1605, 2007.
46. Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the veterans administration cooperative urological research group studies. NCI Monogr 165-170, 1988.
47. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the medical research council trial. The medical research council prostate cancer working party investigators group. Br J Urol 79:235-246, 1997.
48. Kirk D: Immediate vs deferred hormone treatment for prostate cancer: How safe is androgen deprivation? Br J Urol 86:S220, 2000.
49. Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479, 2006.
50. Moul JW, Wu H, Sun L, McLeod DG, et al: Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171:1141-1147, 2004.
51. Shipley WU, Desilvio M, Pilepich MV, et al: Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of rtog protocol 86-10. Int J Radiat Oncol Biol Phys 64:1162-1167, 2006.
52. Iversen P, Tyrrell CJ, Kaisary AV, et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 164:1579-1582, 2000.
53. McLeod DG, Iversen P, See WA, et al: Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97:247-254, 2006.
54. Di Lorenzo G, Perdona S, De Placido S, et al: Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: The role of tamoxifen and radiotherapy. J Urol 174:2197-2203, 2005.
55. Barqawi A, Akduman B, Abouelfadel Z, et al: The use of flutamide as a single antiandrogen treatment for hormone-refractory prostate cancer. BJU Int 92:695-698, 2003.
56. Fleshner NE, Trachtenberg J: Combination finasteride and flutamide in advanced carcinoma of the prostate: Effective therapy with minimal side effects. J Urol 154:1642-1646 (incl discussion), 2005.
57. Ornstein DK, Rao GS, Johnson B, et al: Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology 48:901-905, 1996.
58. Barqawi AB, Moul JW, Ziada A, et al: Combination of low-dose flutamide and finasteride for psa-only recurrent prostate cancer after primary therapy. Urology 62:872-876, 2003.
59. Bañez LL, Blake G, McLeod DG, et al: Phase II trial of combination low-dose flutamide plus finasteride versus low-dose flutamide monotherapy for biochemical recurrence following definitive therapy for prostate cancer: Long-term follow-up. Manuscript in preparation 2007.
60. Bhandari MS, Crook J, Hussain M: Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 23:8212-8218, 2005.
61. Pruthi RS, Derksen JE, Moore D, et al: Phase ii trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res 12:2172-2177, 2006.
62. Smith MR, Manola J, Kaufman DS, et al: Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 24:2723-2728, 2006.
63. Pantuck AJ, Leppert JT, Zomorodian N, et al: Phase ii study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 12:4018-4026, 2006.
64. Smith MR, Kabbinavar F, Saad F, et al: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925, 2005.
65. Schellhammer PF, Venner P, Haas GP, et al: Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157:1731-1735, 1997.
66. Kucuk O, Fisher E, Moinpour CM, et al: Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A southwest oncology group study (SWOG 9235). Urology 58:53-58, 2001.
67. Kassouf W, Tanguay S, Aprikian AG: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169:1742-1744, 2003.
68. Smith DC, Redman BG, Flaherty LE, et al: A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 52:257-260, 1998.
69. Small EJ, Baron A, Bok R: Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80:1755-1759, 1997.
70. Beer TM, Garzotto M, Eilers KM, et al: Phase ii study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol 169:1738-1741, 2003.
71. Dreicer R, Carducci M: E-1899: An eastern cooperative oncology group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. Rev Urol 5(suppl 2):S35-S41, 2003.
72. Nelson JB, Chin JL, Love W, et al: Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC) (abstract 5018). J Clin Oncol 25(18S):239s, 2007.